Insulin lispro (Lyumjev) vs SAR341402
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
Insulin lispro (Lyumjev)
Marketed by Eli Lilly
NCT03214380 · Phase 3 · completed
The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)
Result source: NCT03952143
SAR341402
Marketed by Sanofi
NCT03211858 · Phase 3 · completed
The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.
Reported efficacy
Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)
Result source: NCT03211858
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin lispro (Lyumjev) | SAR341402 |
|---|---|---|
| HbA1c, change | -0.4% vs -0.4%vs Insulin Lispro (Humalog)NCT032143801 other result
| -0.4% vs -0.3%vs NovoLog/NovoRapidNCT032118581 other result
|
| Body weight, change (kg) | —Not reported | —Not reported |
| HbA1c below 7% | —Not reported | 19.6% vs 18.2%vs NovoLog/NovoRapidNCT032118581 other result
|
| Fasting plasma glucose, change | —Not reported | -0.1 vs -0.3vs NovoLog/NovoRapidNCT032118581 other result
|
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- Insulin lispro (Lyumjev)
- -0.4% vs -0.4%vs Insulin Lispro (Humalog)NCT03214380
1 other result
- -0.6% vs -0.6% NCT03952143
- SAR341402
- -0.4% vs -0.3%vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.3% vs -0.3% NCT03211858
Body weight, change (kg)
- Insulin lispro (Lyumjev)
- —Not reported
- SAR341402
- —Not reported
HbA1c below 7%
- Insulin lispro (Lyumjev)
- —Not reported
- SAR341402
- 19.6% vs 18.2%vs NovoLog/NovoRapidNCT03211858
1 other result
- 16.6% vs 14.5% NCT03211858
Fasting plasma glucose, change
- Insulin lispro (Lyumjev)
- —Not reported
- SAR341402
- -0.1 vs -0.3vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.5 vs -0.2 NCT03211858
3-point MACE (% with event)
- Insulin lispro (Lyumjev)
- —Not reported
- SAR341402
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin lispro (Lyumjev): 4 of 4 rows · SAR341402: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin lispro (Lyumjev) | SAR341402 |
|---|---|---|
| Dropout rate | —a NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results— NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 —LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence —LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence —15 U NCT03286751 · Phase 1 · registry result, not featured evidence —30 U NCT03286751 · Phase 1 · registry result, not featured evidence —7 U NCT03286751 · Phase 1 · registry result, not featured evidence —15 U NCT03305822 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination —LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence | 12.3% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | —a NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results— NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.7% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 —LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence —LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence —15 U NCT03286751 · Phase 1 · registry result, not featured evidence —30 U NCT03286751 · Phase 1 · registry result, not featured evidence —7 U NCT03286751 · Phase 1 · registry result, not featured evidence —15 U NCT03305822 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination —LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence | 2.7% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Serious AEs | 7.7%a NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results8.4% NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.7% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence 0%LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence 0%15 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%30 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%7 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%15 U NCT03305822 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination 0%LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence | 12% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | a nasopharyngitis 14% upper respiratory tract infection 8% diarrhoea 3.3% NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 15 more resultsupper respiratory tract infection 5.3% NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 injection site reaction 5.6% NCT03341312 · Phase 1 · registry result, not featured evidence injection site reaction 2.9% NCT03341312 · Phase 1 · registry result, not featured evidence 15 U headache 10% nausea 5% injection site reaction 2.5% NCT03286751 · Phase 1 · registry result, not featured evidence 30 U headache 14.6% injection site reaction 14.6% nausea 7.3% NCT03286751 · Phase 1 · registry result, not featured evidence 7 U headache 15% injection site reaction 2.5% nausea 2.5% NCT03286751 · Phase 1 · registry result, not featured evidence 15 U headache 5.3% vessel puncture site thrombosis 5.3% NCT03305822 · Phase 1 · registry result, not featured evidence 15 U infusion site pain 12% catheter site bruise 8% vessel puncture site bruise 8% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U injection site pain 11.5% application site erythema 7.7% catheter site bruise 7.7% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U catheter site pain 10.7% catheter site swelling 7.1% application site erythema 3.6% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U catheter site bruise 7.7% infusion site erythema 7.7% infusion site swelling 7.7% NCT03232983 · Phase 1 · registry result, not featured evidence headache 6.7% back pain 0% thrombophlebitis 0% NCT02703337 · Phase 1 · registry result, not featured evidence back pain 0% headache 0% thrombophlebitis 0% NCT02703337 · Phase 1 · registry result, not featured evidence · combination thrombophlebitis 6.9% back pain 0% headache 0% NCT02703337 · Phase 1 · registry result, not featured evidence thrombophlebitis 10.3% back pain 0% headache 0% NCT02703337 · Phase 1 · registry result, not featured evidence | nasopharyngitis 11.3% upper respiratory tract infection 7.3% influenza 5% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 14 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin lispro (Lyumjev)
+ 7 further endpoints in the CSV export.
SAR341402
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin lispro (Lyumjev)'s landscape · SAR341402's landscape